

# Summit Therapeutics PLC

12:15 14 Mar 2019

## Summit Therapeutics shows off potential of Discuva platform at Berlin conference

Summit Therapeutics PLC (LON:SUMM) has unveiled two new presentations at an industry conference in Berlin.

The presentations show off the potential of Summit's Discuva platform, which it is using to identify and develop new antibiotics that infections such as gonorrhoea and staph aren't resistant to.

**READ: Summit's gonorrhoea antibiotic showing promise**

Several programmes of new mechanism antibiotics have emerged from the Discuva Platform, including one targeting gonorrhoea and another targeting ESKAPE pathogens.

Both of those programmes are being discussed at the conference.

"Antimicrobial resistance is a worldwide problem. We need to see scientific innovation to prevent an era of untreatable infections," said Summit's president of R&D, David Roblin.

"Through the Discuva Platform, we are using novel science to create targeted, new mechanism antibiotics that are optimised against resistance development.

"Our goal is to develop the most appropriate drug for a specific patient, thereby improving patient outcomes and giving physicians options to address the spread of AMR."

Summit shares were up 1.6% to 30.5p in early afternoon trading on Thursday.

**Price:** 29.9p

**Market Cap:** £47.96M

### 1 Year Share Price Graph



March 2018 September 2018 March 2019

### Share Information

**Code:** SUMM

**Listing:** AIM

**52 week High Low**  
209.00p 9.50p

**Sector:** Pharma & Biotech

**Website:** www.summitplc.com

### Company Synopsis:

Summit Therapeutics is a leader in antibiotic innovation. Summit's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by *C. difficile*, *N.*

### Author:

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

**action@proactiveinvestors.com**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content

published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.